On 29 November 2023, Australian Pharmaceutical Industries Pty Ltd, a wholly-owned subsidiary of Wesfarmers Limited, acquired 100 per cent of the shares in SILK Laser Australia Limited (‘SILK’, ASX:SLA) via a Scheme of Arrangement. As a result, SLA shares were suspending from close of trading on the ASX on 16 November 2023 and it was delisted from the ASX on 30 November 2023. SILK forms part of the Wesfarmers Health division, complementing the Clear Skincare business by providing additional scale and efficiency benefits in the attractive and growing market for medical aesthetics products and services. Further information on these businesses can be found here.
SLA TRANSACTION NEWS
- 29.11.23 - Completion of SILK acquisition
- 10.10.23 - SLA: Despatch of Scheme Booklet
- 04.10.23 - SLA: Approval of Scheme Booklet and Convening Meeting
- 26.06.23 - Wesfarmers Health and SILK enter Scheme Implementation Deed
- 26.06.23 - SLA: SILK Enters into Binding Implementation Deed with API
- 01.06.23 - Notice of ceasing to be a substantial holder for SLA
- 30.05.23 - SLA:API Does Not Exercise Matching Rights Under Process Deed
- 19.04.23 - Wesfarmers Health proposal to acquire SILK Laser Australia
- 19.04.23 - Notice of initial substantial holder for SLA
- 19.04.23 - SLA: Non-Binding Indicative Acquisition Proposal From API
SLA SHARES
SLA Scheme Participants and former SLA shareholders should direct any queries to Computershare Investor Services Pty Limited at the below details:
Postal Address:
GPO Box 2975
Melbourne VIC 3001
Australia
Phone contact
+61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Email contact
Please visit the Computershare website and complete a secure online form query via the link.